Fierce Biotech Next Gen 2023

A new wave of cell therapies and genetic medicines are revolutionizing how we treat and potentially cure certain diseases. While new therapies are gaining steam and starting to change patients’ lives, reimbursement and access challenges remain. Experts on this panel will discuss today’s challenges and what the future holds for potentially lifesaving gene editing tools and cell therapies.  

With the ongoing complexities of clinical treatment journeys, central labs remain a vital component in the supply chain for developing and distributing personalized lifesaving therapies. To design resilient, future-focused logistic solutions that operate at lightspeed, providers must understand the unique lab products and processes to ensure final mile delivery to and from patients across the globe.

Join patient-centric supply chain expert Marco Hogenboom for an insightful discussion on how to accelerate the delivery of advanced therapies in an unpredictable environment through supply chain customization from clinical to commercialization.

This presentation will explore:
• Key trends, global forecasts and growth drivers in the complex and highly competitive central labs market
• Centralized and regionalized approaches that mobilize your ability to pivot to the needs of the patient and client
• Advanced technology impacting the distribution of personalized therapies and enhancing study outcomes including mRNA vaccines, AI and data-based evidence• Ensuring cold chain integrity and 24/7 real-time traceability with temperature-controlled packaging solutions that are changing the game
• Actionable lessons learned and best practices to drive efficiency and advance the scale and availability of precision medicine
• Looking ahead: changes to regulatory framework, industry demand and patient needs

Early-stage biotech companies historically have had limited options to get their first asset to market. In most cases, they lose ownership and control of their asset by pursuing deals with larger partners or take upon themselves massive financial risk to invest in becoming a fully integrated company. In this session, we’ll discuss how some biotechs are flipping these traditional models to their advantage, empowering themselves to chart their own future, minimize launch risk, and maximize asset value.

Launching a new drug is far from straightforward, and it’s becoming increasingly difficult to craft and execute a successful launch strategy. How are companies navigating the challenges and approaching launches differently? A panel of industry experts will dive into that question and share the latest winning strategies

Therapeutic mAbs continues to be a rapidly growing field and a promising solution to address many unmet medical needs. To meet market demands, mAb developers are actively looking for more efficient and robust production platforms to reduce timelines and overall development costs. Throughput, productivity, and scalability of the expression platform as well as availability of well-documented production cell lines are key selection criteria when initiating a mAbs campaign. To this end, Gibco™ ExpiCHO™ and Expi293™ Expression Systems are complete platforms that can speed up mAbs discovery by enabling rapid, high-yield, and scalable protein production from mammalian (ExpiCHO™ and Expi293™) cells. The Thermo Scientific™ Cytomat™ series is the leading brand of incubators in lab automation. TRUE orbital shaking ensures superior cell growth for cells in suspension, which is critical for mAb candidate expression. These proven solutions back by a team of SME enable mAb developers to get to key milestones faster.

Antibody-drug conjugates have been around for more than 20 years and there's now more than a dozen on the market worldwide. So why all of a sudden are Big Pharmas scrambling to strike new deals in the ADC space? Billions of dollars in licensing deals have been put on the line in the past year. This panel will dive into the new frontier of ADCs: where they are headed in the clinic—and whether they have a future beyond cancer.